The CCR5 inhibitor maraviroc was shown to reduce aortic plaque size when treating atherosclerotic mice (395) but also to decrease atherosclerosis progression in HIV patients (396) and thus represents another interesting target for further studies. The gene discussed is CCR5; the disease is atherosclerosis.